Enhanced In Vivo Absorption of Itraconazole via Stabilization of Supersaturation Following Acidic-to-Neutral pH Transition

REFERENCES

• Bohme A., Just-Nubling G., Bergmann L., Shah P. M., Stille W., Hoelzer D. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J. Antimicrob. Chemother. 1996; 38: 953–961
   PubMed Web of Science ®Google Scholar
• Denning D. W. Invasive aspergillosis. Clin. Infect. Dis. 1998; 26: 781–803
   PubMed Web of Science ®Google Scholar
• Denning D. W., Lee J. Y., Hostetler J. S., Pappas P., Kauffman C. A., Dewsnup D. H., Galgiani J. N., Graybill J. R., Sugar A. M., Catanzaro A. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 1994; 97: 135–44
   PubMed Web of Science ®Google Scholar
• Fridkin S., Jarvis W. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 1996; 9: 499–511
   PubMed Web of Science ®Google Scholar
• Gao P., Guyton M. E., Huang T., Bauer J. M., Stefanski K. J., Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm. 2004; 30: 221–229
   PubMed Web of Science ®Google Scholar
• Glasmacher A., Prentice A., Gorschluter M., Engelhart S., Hahn C., Djulbegovic B., Schmidt-Wolf I. G. H. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. 2003; 21: 4615–4626
   PubMed Web of Science ®Google Scholar
• Grant S. M., Clissold S. P. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1998; 37: 310–344
   Google Scholar
• Groll A., Shah P., Mentzel C., Schneider M., Just-Neubling G., Huebling G., Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 1996; 33: 23–32
   PubMed Web of Science ®Google Scholar
• Gubbins P. O., Gurley B. J., Bowman J. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J. Pharm. Biomed. Anal. 1998; 16: 1005–1012
   PubMed Web of Science ®Google Scholar
• Hardin T. C., Graybill J. R., Fetchick R., Woestenborghs R., Rinaldi M. G., Kuhn J. G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 1988; 32: 1310–1313
   PubMed Web of Science ®Google Scholar
• http://www.sporanox.com Janssen, L. P. (2006 June). Sporanox (Itraconazole capsules). Prescribing Information. Beerse, Belgium: Janssen Pharmaceutica. Available from:
   Google Scholar
• Janssens S., de Armas H. N., Remon J. P., Van den Mooter G. The use of a new hydrophilic polymer, Kollicoat IR(R), in the formulation of solid dispersions of Itraconazole. Eur. J. Pharm. Sci. 2007; 30: 288–294
   PubMed Web of Science ®Google Scholar
• Jung J.-Y., Yoo S. D., Lee S.-H., Kim K.-H., Yoon D.-S., Lee K.-H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm. 1999; 187: 209–218
   PubMed Web of Science ®Google Scholar
• Lee S., Nam K., Kim M. S., Jun S. W., Park J. S., Woo J. S., Hwang S. J. Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch. Pharm. Res. 2005; 28: 866–874
   PubMed Web of Science ®Google Scholar
• Lewis R. E., Wiederhold N. P., Klepser M. E. In vitro pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicro. Agents Chemother. 2005; 94: 5–951
   Google Scholar
• Lin S.-J., Schranz J., Tentsch S. M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin. Infect. Dis. 2001; 32: 358
   PubMed Web of Science ®Google Scholar
• McKinsey D. S., Wheat L. J., Cloud G. A., Pierce M., Black J. R., Bamberger D. M., Goldman M., Thomas C. J., Gutsch H. M., Moskovitz B., Dismukes W. E., Kauffman C. A. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency. Clin. Infect. Dis. 1999; 28: 1049
   PubMed Web of Science ®Google Scholar
• Miller D. A., Gamba M., Sauer D., Purvis T. P., Clemens N. T., Williams R. O., III. Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence. Int. J. Pharm. 2007; 330: 61–72
   PubMedGoogle Scholar
• Miller D. A., McConville J. T., Yang W., Williams R. O., III, McGinity J. W. Hot-melt extrusion for enhanced delivery of drug particles. J. Pharm. Sci. 2007; 96: 361–376
   PubMed Web of Science ®Google Scholar
• Mouy R., Veber F., Blanche S., Donadieu J., Brauner R., Levron J. C., Griscelli C., Fischer A. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J. Pediatr. 1994; 125(Dec)998–1003
   PubMedGoogle Scholar
• Myoken Y., Sugata T., Kyo T., Fujihara M., Mikami Y. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. J. Periodontol. 2002; 73: 33–38
   PubMed Web of Science ®Google Scholar
• Okimoto K., Miyake M., Ibuki R., Yasumura M., Ohnishi N., Nakai T. Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose. Int. J. Pharm. 1997; 159: 85–93
   Web of Science ®Google Scholar
• Overhoff K. A., Moreno A., Miller D. A., Johnston K. P., Williams R. O., III. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int. J. Pharm. 2007; 336: 122–132
   PubMed Web of Science ®Google Scholar
• Peeters J., Neeskens P., Tollenaere J. P., Van Remoortere P., Brewster M. Characterization of the interaction of 2-hydroxypropyl-B-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 2002; 91: 1414–1422
   PubMed Web of Science ®Google Scholar
• Petereit H.-U., Weisbrod W. Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers. Eur. J. Pharm. Biopharm. 1999; 47: 15–25
   PubMed Web of Science ®Google Scholar
• Rambali B., Verreck G., Baert L., Massart D. L. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm. 2003; 29: 641–652
   PubMed Web of Science ®Google Scholar
• Selik R., Karon J., Ward J. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J. Infect. Dis. 1997; 176: 632–636
   PubMed Web of Science ®Google Scholar
• Shin-Etsu. Certificate of Analysis—Hypromellose Phthalate. NF HP-55. Shin-Etsu Chemical Co Tokoyo, Japan 2007
   Google Scholar
• Six K., Daems T., de Hoon J., Van Hecken A., Depre M., Bouche M.-P., Prinsen P., Verreck G., Peeters J., Brewster M. E., Van den Mooter G. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur. J. Pharm. Sci. 2005; 24: 179–186
   PubMed Web of Science ®Google Scholar
• Six K., Leuner C., Dressman J., Verreck G., Peeters J., Blaton N., Augustijns P., Kinget R., Van den Mooter G. Thermal properties of hot-stage extrudates of itraconazole and eudragit E100. Phase separation and polymorphism. J. Therm. Anal. Calorim. 2002; 68: 591–601
   Web of Science ®Google Scholar
• Six K., Verreck G., Peeters J., Augustijns P., Kinget R., Van den Mooter G. Characterization of glassy itraconazole: A comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. Int. J. Pharm. 2001; 213: 163–173
   PubMed Web of Science ®Google Scholar
• Six K., Verreck G., Peeters J., Binnemans K., Berghmans H., Augustijns P., Kinget R., Van den Mooter G. Investigation of thermal properties of glassy itraconazole: Identification of a monotropic mesophase. Thermochimica. Acta. 2001; 376: 175–181
   Web of Science ®Google Scholar
• Six K., Verreck G., Peeters J., Brewster M. E., Van den Mooter G. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J. Pharm. Sci. 2004; 93: 124–131
   PubMed Web of Science ®Google Scholar
• Suzuki H., Sunada H. Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem. Pharm. Bull. 1998; 46: 482–487
   PubMed Web of Science ®Google Scholar
• Van den Mooter G., Weuts I., De Ridder T., Blaton N. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int. J. Pharm. 2006; 316: 1–6
   PubMed Web of Science ®Google Scholar
• Vaughn J. M., McConville J. T., Burgess D., Peters J. I., Johnston K. P., Talbert R. L., Williams R. O., III. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 2006; 63: 95–102
   PubMed Web of Science ®Google Scholar
• Verreck G., Chun I., Peeters J., Rosenblatt J., Brewster M. E. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm. Res. 2003; 20: 810–817
   PubMed Web of Science ®Google Scholar
• Verreck G., Six K., Van den Mooter G., Baert L., Peeters J., Brewster M. E. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion—Part I. Int. J. Pharm. 2003; 251: 165–174
   PubMed Web of Science ®Google Scholar
• Wang X., Michoel A., Van den Mooter G. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int. J. Pharm. 2005; 303: 54–61
   PubMed Web of Science ®Google Scholar
• Yamashita K., Nakate T., Okimoto K., Ohike A., Tokunaga Y., Ibuki R., Higaki K., Kimura T. Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 2003; 267: 79–91
   PubMed Web of Science ®Google Scholar
• Yamazaki T., Kume H., Yamashita E., Murase S., Arisawa M. Epidemiology of visceral mycoses: Analysis on data in annual of the pathological autopsy cases in Japan [abstract P-117]. 13th Congress of the International Society for Human and Animal Mycology, ParmaItaly, 1997
   Google Scholar
• Ye G., Wang S., Heng P. W. S., Chen L., Wang C. Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. Int. J. Pharm. 2007; 337: 80–87
   PubMed Web of Science ®Google Scholar
• Yokoi Y., Yonemochi E., Terada K. Effects of sugar ester and hydroxypropyl methylcellulose on the physicochemical stability of amorphous cefditoren pivoxil in aqueous suspension. Int. J. Pharm. 2005; 290: 91–99
   PubMed Web of Science ®Google Scholar
• Yoo S. D., Lee S.-H., Kang E., Jun H., Jung J.-Y., Park J. W., Lee K.-H. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev. Ind. Pharm. 2000; 2: 7–34
   Google Scholar
• Zhou H., Goldman M., Wu J., Woestenborghs R., Hassell A. E., Lee P., Baruch A., Pesco-Koplowitz L., Borum J., Wheat L. J. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol. 1998; 38: 593–602
   PubMed Web of Science ®Google Scholar